Welcome to NeuroImmuneX: A Platform for Transformative Neuroscience
Our PET imaging platform accelerates breakthrough treatments by precisely targeting neuroinflammation, a key factor in brain disorders, and neurodegeneration.
Contact Us
Our Science: Tackling Neuroinflammation for Breakthrough Therapies
At NeuroImmuneX, we're redefining neuroscience drug development by targeting the complex role of neuroinflammation in brain diseases. Our innovative approach bridges the gap between fundamental neuroimmune mechanisms and clinical applications.
Our translational research platform accelerates the bench-to-bedside journey, focusing on neurological conditions with significant unmet needs where conventional approaches have fallen short.
Neuroimmune Focus
Targeting the immune-brain axis to address underlying disease mechanisms rather than just symptoms.
Translational Research
Rapid translation of scientific discoveries into clinical applications through innovative trial designs.
High-Need Conditions
Prioritizing neurological disorders with limited treatment options and significant patient impact.
PET Imaging-Enabled Drug Discovery Platform
Our proprietary PET imaging technology forms the backbone of our drug discovery platform, offering unprecedented insights into disease progression and treatment response.
Biomarker Tracking
Non-invasive monitoring of neuroinflammatory biomarkers provides real-time disease insights without invasive procedures.
Accelerated Decisions
Rapid assessment of therapeutic efficacy enables quick go/no-go decisions, reducing development timelines and costs.
Target Validation
Direct visualization of drug-target engagement confirms mechanism of action and supports evidence-based development strategies.
Operational, Analytic, and Strategic Excellence
Operational Excellence
Streamlined processes and integrated workflows ensure consistent quality and timeline adherence across all development stages.
Analytic Mastery
Advanced AI-powered data analysis extracts meaningful insights from complex neuroimaging and clinical data.
Strategic Vision
Forward-thinking approach to portfolio management and partnership development maximizes resource efficiency.
Our three pillars of excellence work in harmony to accelerate drug development timelines while maintaining scientific rigor and regulatory compliance, reducing time-to-market for critical neurotherapeutics.
Leadership & Expert Team
Led by industry veterans with extensive neuroscience expertise, our multidisciplinary team combines decades of experience in drug development, neuroimmunology, and advanced imaging technologies.
Research Excellence
Our scientists have pioneered breakthrough discoveries in neuroinflammation pathways and biomarker development.
Development Expertise
Our development team has successfully guided multiple CNS therapeutics through clinical trials to market approval.
Advisory Network
Our advisory board includes world-renowned neurologists, imaging specialists, and pharmaceutical innovators.
Get in Touch & Join Our Mission
Partner with NeuroImmuneX to accelerate the development of revolutionary treatments for neurological disorders. Whether you're interested in collaboration, investment opportunities, or joining our team, we welcome your inquiries.
1
Partnership Opportunities
Explore co-development initiatives, research collaborations, and licensing opportunities for our proprietary technologies.
2
Stay Informed
Subscribe to our newsletter for the latest updates on neuroinflammation research and company developments.
3
Join Our Team
View current openings for scientists, clinicians, and business professionals passionate about neuroscience innovation.
Scientific Publications
Alzheimer's Disease Research
Singhal et al. Clinical Nuclear Medicine May 2025
Multiple Sclerosis Findings
Singhal et al. AAN 2024
Our research teams continue to publish groundbreaking findings in leading peer-reviewed journals and present at prestigious conferences, advancing the scientific understanding of neuroinflammatory mechanisms.
Ongoing Phase II Clinical Trials built on our work
Each trial is built on our PET imaging research for real-time assessment of neuroinflammatory status, enabling precision and enhanced patient selection. Our trials are designed with regulatory considerations at the forefront, with potential for accelerated approval pathways based on the critical unmet needs they address.